Your session is about to expire
← Back to Search
Triple Drug Therapy for Mantle Cell Lymphoma
Study Summary
This trial is testing a combination of drugs to treat mantle cell lymphoma, a cancer of the lymph nodes. The drugs work in different ways to kill cancer cells or stop their growth.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My lymphoma is confirmed as mantle cell type.I am a man who will use highly effective birth control and not donate sperm during and for 6 months after treatment.My cancer cells have a specific genetic marker (t(11;14)).I cannot take medicine by mouth due to a digestive condition.A specialist confirmed I have mantle cell lymphoma through a biopsy.I have been tested for hepatitis C; my PCR test is negative.I have had another type of cancer that might interfere with this study.I do not have any active infections, except for nail fungus.I have been diagnosed with mantle cell lymphoma and have not received previous therapy for it.You must use highly effective birth control methods such as female or male sterilization, hormonal contraceptives that stop ovulation or intrauterine devices (IUDs) to prevent pregnancy during the trial. Examples of effective IUDs include hormone-releasing IUDs or copper IUDs.I can take care of myself and am up and about more than half of my waking hours.I understand and commit to reliable contraception methods during the trial.I had or have hidden hepatitis B but with undetectable virus levels, and agree to monthly tests and preventive treatment.I need to take warfarin.I agree to use highly effective birth control or remain abstinent during and after treatment.I am a woman who can still have children.I understand and commit to reliable contraception methods during the trial.I will use protection or abstain from sex to prevent pregnancy during and 6 months after treatment.I understand and commit to reliable contraception methods during the trial.I agree to either not have sex or use birth control, and not donate sperm.My kidney function is within the required range.I have a significant history of liver problems.I agree to use effective birth control or remain abstinent and not donate sperm while on obinutuzumab and for 6 months after.I had skin cancer, early-stage melanoma, cervical cancer in situ, low-risk prostate or thyroid cancer, or DCIS but am now in remission.My cancer is Cyclin D1 positive.I have not received any treatment for lymphoma, except possibly steroids for urgent symptoms.I haven't had any live-virus vaccines in the last 28 days and don't need any during the study.I agree to use highly effective birth control or remain abstinent during and after treatment.I haven't taken certain strong medications or eaten grapefruit and similar fruits within a week before starting venetoclax.I do not have any severe illnesses that would interfere with the study or increase my risk.My kidney or liver problems are due to my cancer, as confirmed by my doctor.I have HIV with a CD4 count over 400, undetectable viral load, and no AIDS-defining illness.My kidney function is within the required range.I am a woman who can still have children.I can take care of myself and am up and about more than half of my waking hours.I haven't had major surgery in the last 6 weeks, except for diagnosis or line placement.
- Group 1: Venetoclax, bendamustine, obinutuzumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is Bendamustine a safe drug for patients to use?
"Due to Bendamustine's limited efficacy data, it was assigned a safety score of 2 out of 3."
Are there any openings remaining for individuals to join this medical research?
"Clinicaltrials.gov states that this research endeavour is no longer recruiting patients, having first been posted on April 11th 2019 and last edited November 2nd 2022. However, 2063 other trials are still actively looking for study participants."
What prior research has utilized Bendamustine as a therapeutic agent?
"At present, there are a total of 344 Bendamustine trials occurring around the globe. Out of these, 52 investigations are currently in their third phase and Edmonton, Alberta houses most studies involving this medication. Across 13082 distinct sites worldwide, patients can access clinical research for Bendamustine."
What is the current enrollment size of this investigation?
"This particular study is no longer accepting applicants, as it was first posted on April 11th 2019 and last updated November 2nd 2022. However, if you are searching for alternative trials to apply to, there are 1,719 ccnd1 positive studies and 344 Bendamustine clinical studies that require participants."
What conditions is Bendamustine usually prescribed for?
"Bendamustine is traditionally utilized to treat refractory mantle cell lymphoma, but can also be applied as a therapeutic approach for patients suffering from follicular lymphoma, chronic lympocytic leukemia, and hodgkin disease."
Share this study with friends
Copy Link
Messenger